Are any of these ASX stocks, near their record highs still offering an opportunity to buy?

The following 3 ASX stocks are hovering around their 52-week highs backed by impressive operational milestones and strategic developments that have significantly improved their long-term earnings outlook.

GenusPlus Group Limited (ASX: GNP)

GenusPlus Group Limited is now hovering around its 52-week highs and the stock is up 17% in the past one month and 61.2% year-to-date.
The company on 20 May 2026 announced a heavily supported $200 million institutional placement which will fund the transformational acquisition of MPC Kinetic Holdings and expand the scale of its infrastructure operations.

Management recently upgraded FY2026 earnings guidance with normalised EBITDA now expected between $96 million and $100 million compared to normalised FY2025 EBITDA of $67.4 million which reflects strong year-on-year growth of around 42-48%.

Genus at the of writing has a market capitalisation of $1.84 billion while about $2-$3 million of the expected EBITDA growth is projected to come from the acquisition of Railtrain Holdings which was completed on 1 April 2026.

The latest announcement highlights Genus’ acquisition-led growth strategy along with the strong support from institutional investors for funding reflects confidence in the company’s long-term earnings outlook.

Smartgroup Corporation Limited (ASX: SIQ) 

Smartgroup Corporation Limited reached a new 52-week high of $11.7 on Thursday after the company on 20 May 2026 announced an on-market share buy-back of up to $20 million.

The company at the time of writing has a market capitalisation of $1.6 billion. The stock price has surged 53% over the last 12 months because investors have recognised the strength of its capital light business model and long term structural growth opportunities.

Smartgroup in 2025 reported another strong financial result as revenue rose 8% year-on-year to $329.3 million while EBITDA increased 14% to $135.3 million and NPATA grew 11% to $80.2 million.
Management expects EBITDA margins to reach the mid-40% range during 2027 as automation initiatives and simpler operations are expected to improve scalability across the business.

The current annual yield is 4.54% while the company has also added AI capabilities across multiple parts of its operations including AI-based chat support and internal AI agents which improve productivity and customer experience.

Anteris Technologies Global Corp. (ASX: AVR) 

Anteris Technologies Global Corp has stood out among ASX stocks hovering around their 52-week highs while the stock has already surged 58% year-to-date.

The company during Q1 2026 completed major capital raises worth US$320 million which improved the balance sheet and supported funding for the PARADIGM Trial along with the planned global commercialisation of the DurAVR THV System.

The company’s core focus is the design along with development and commercialisation of advanced medical devices that help restore healthy heart function.

Q1 2026 also showed solid progress across the PARADIGM Trial as patient enrolment remained active in Europe alongside further advancement in global recruitment activities.

With the U.S. now operational and the first patients already enrolled, the company is focused on executing its strategy and building momentum ahead of the commercial launch of DurAVR.

The market capitalisation at the time of writing stood at $1.18 billion while R&D expenditure for Q1 reached US$17.5 million as the company invested aggressively to achieve necessary progress.

(Source: Company Announcements)